Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Pipex Pharmaceuticals has acquired an oral, once-daily candidate which has completed a 160-patient, multi-center, double-blind, randomized, placebo-controlled Phase II clinical trial for the treatment of rheumatoid arthritis.
Subscribe to our email newsletter
Oral dnaJP1 is a once-daily epitope specific immunotherapy for rheumatoid arthritis (RA) patients. Oral dnaJP1 is a heat shock protein (hsp)-derived peptide which was previously identified as a contributor of T-cell mediated inflammation in RA.
Oral dnaJP1 is said to have been developed using computer-aided, rational drug design techniques which resulted in a short synthetic peptide derived from a hsp dnaJ.
Oral dnaJP1 is a new chemical entity which is covered by issued US and international patent filings including composition of matter and methods of use patents. This Phase II clinical program was supported by a $5 million grant from the National Institutes of Health.
Nicholas Stergis, Pipex’s CEO, said: “We are pleased to have broadened our therapeutic pipeline of products with the acquisition of this innovative program. Oral dnaJP1 certainly complements our existing clinical stage immunology programs which include Trimesta, our oral Phase II/III clinical program in multiple sclerosis and our CD4 inhibitor technology.”